Stockwinners Market Radar for November 23, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

09:26 EST Ziopharm presents 'encouraging' clinical data for Controlled IL-12 - Ziopharm Oncology announced the presentation of new interim analyses of clinical data from two ongoing substudies in its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor, for the treatment of recurrent or progressive glioblastoma multiforme in adults, at the 2019 Society for Neuro-Oncology, or SNO, Annual Meeting in Phoenix. "Recurrent GBM is a complex disease which grows by walling itself off from the immune system, making it so devastating. It appears that placing IL-12 within the tumor and then controlling the production of this cytokine, drives T cells into the tumor, enabling the immune system to adapt, which leads to anti-tumor activity," said Laurence Cooper, M.D., Ph.D., CEO of Ziopharm. "We are encouraged by the findings presented at SNO, as we advance the clinical development of Controlled IL-12 as a monotherapy and in combination with immune checkpoint inhibitors, including a phase 2 study which is currently enrolling."

09:22 EST Takeda Pharmaceutical presents long-term data showing Alunbrig 'superiority' - Takeda Pharmaceutical Company Limited announced updated data from the Phase 3 ALTA-1L trial, which evaluated Alunbrig versus crizotinib in adults with advanced anaplastic lymphoma kinase-positive, or ALK+, non-small cell lung cancer who had not received a prior ALK inhibitor. Results show after more than two years of follow-up, Alunbrig reduced the risk of disease progression or death by 76% as assessed by investigators in newly diagnosed patients whose disease had spread to the brain at time of enrollment. Alunbrig also demonstrated a 57% reduction in risk of disease progression or death in all patients. These data will be presented during the Presidential Session at the 2019 European Society for Medical Oncology, or ESMO, Asia Congress on Saturday, November 23 in Singapore.